Eintrag weiter verarbeiten
Genetics of parathyroid tumours
Gespeichert in:
| Zeitschriftentitel: | Journal of Internal Medicine |
|---|---|
| Personen und Körperschaften: | |
| In: | Journal of Internal Medicine, 280, 2016, 6, S. 574-583 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
Wiley
|
| Schlagwörter: |
| author_facet |
Thakker, R. V. Thakker, R. V. |
|---|---|
| author |
Thakker, R. V. |
| spellingShingle |
Thakker, R. V. Journal of Internal Medicine Genetics of parathyroid tumours Internal Medicine |
| author_sort |
thakker, r. v. |
| spelling |
Thakker, R. V. 0954-6820 1365-2796 Wiley Internal Medicine http://dx.doi.org/10.1111/joim.12523 <jats:title>Abstract</jats:title><jats:p>Primary hyperparathyroidism (<jats:styled-content style="fixed-case">PHPT</jats:styled-content>), due to parathyroid tumours, may occur as part of a complex syndrome or as an isolated (nonsyndromic) disorder, and both forms can occur as familial (i.e. hereditary) or nonfamilial (i.e. sporadic) disease. Syndromic <jats:styled-content style="fixed-case">PHPT</jats:styled-content> includes multiple endocrine neoplasia (<jats:styled-content style="fixed-case">MEN</jats:styled-content>) types 1 to 4 (<jats:styled-content style="fixed-case">MEN</jats:styled-content>1 to <jats:styled-content style="fixed-case">MEN</jats:styled-content>4) and the hyperparathyroidism‐jaw tumour (<jats:styled-content style="fixed-case">HPT</jats:styled-content>‐<jats:styled-content style="fixed-case">JT</jats:styled-content>) syndrome. Syndromic and hereditary <jats:styled-content style="fixed-case">PHPT</jats:styled-content> are often associated with multiple parathyroid tumours, in contrast to sporadic <jats:styled-content style="fixed-case">PHPT</jats:styled-content>, in which single parathyroid adenomas are more common. In addition, parathyroid carcinomas may occur in ~15% of patients with the <jats:styled-content style="fixed-case">HPT</jats:styled-content>‐<jats:styled-content style="fixed-case">JT</jats:styled-content> syndrome. <jats:styled-content style="fixed-case">MEN</jats:styled-content>1 is caused by abnormalities of the <jats:italic><jats:styled-content style="fixed-case">MEN</jats:styled-content>1</jats:italic> gene which encodes a tumour suppressor; <jats:styled-content style="fixed-case">MEN</jats:styled-content>2 and <jats:styled-content style="fixed-case">MEN</jats:styled-content>3 are due to mutations of the rearranged during transfection (<jats:italic><jats:styled-content style="fixed-case">RET</jats:styled-content></jats:italic>) proto‐oncogene, which encodes a tyrosine kinase receptor; <jats:styled-content style="fixed-case">MEN</jats:styled-content>4 is due to mutations of a cyclin‐dependent kinase inhibitor (<jats:italic><jats:styled-content style="fixed-case">CDNK</jats:styled-content>1B</jats:italic>); and <jats:styled-content style="fixed-case">HPT</jats:styled-content>‐<jats:styled-content style="fixed-case">JT</jats:styled-content> is due to mutations of cell division cycle 73 (<jats:italic><jats:styled-content style="fixed-case">CDC</jats:styled-content>73</jats:italic>), which encodes parafibromin. Nonsyndromic <jats:styled-content style="fixed-case">PHPT</jats:styled-content>, which may be hereditary and referred to as familial isolated hyperparathyroidism, may also be due to <jats:italic><jats:styled-content style="fixed-case">MEN</jats:styled-content>1, <jats:styled-content style="fixed-case">CDC</jats:styled-content>73</jats:italic> or calcium‐sensing receptor (<jats:italic><jats:styled-content style="fixed-case">CASR</jats:styled-content></jats:italic>) mutations. In addition, ~10% of patients presenting below the age of 45 years with nonsyndromic, sporadic <jats:styled-content style="fixed-case">PHPT</jats:styled-content> may have <jats:italic><jats:styled-content style="fixed-case">MEN</jats:styled-content>1</jats:italic>,<jats:italic> <jats:styled-content style="fixed-case">CDC</jats:styled-content>73</jats:italic> or <jats:italic><jats:styled-content style="fixed-case">CASR</jats:styled-content></jats:italic> mutations, and overall more than 10% of patients with <jats:styled-content style="fixed-case">PHPT</jats:styled-content> will have a mutation in one of 11 genes. Genetic testing is available and of value in the clinical setting, as it helps in making the correct diagnosis and planning the management of these complex disorders associated with parathyroid tumours.</jats:p> Genetics of parathyroid tumours Journal of Internal Medicine |
| doi_str_mv |
10.1111/joim.12523 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTExMS9qb2ltLjEyNTIz |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTExMS9qb2ltLjEyNTIz |
| institution |
DE-D161 DE-Zwi2 DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 DE-L229 DE-D275 DE-Bn3 DE-Brt1 |
| imprint |
Wiley, 2016 |
| imprint_str_mv |
Wiley, 2016 |
| issn |
1365-2796 0954-6820 |
| issn_str_mv |
1365-2796 0954-6820 |
| language |
English |
| mega_collection |
Wiley (CrossRef) |
| match_str |
thakker2016geneticsofparathyroidtumours |
| publishDateSort |
2016 |
| publisher |
Wiley |
| recordtype |
ai |
| record_format |
ai |
| series |
Journal of Internal Medicine |
| source_id |
49 |
| title |
Genetics of parathyroid tumours |
| title_unstemmed |
Genetics of parathyroid tumours |
| title_full |
Genetics of parathyroid tumours |
| title_fullStr |
Genetics of parathyroid tumours |
| title_full_unstemmed |
Genetics of parathyroid tumours |
| title_short |
Genetics of parathyroid tumours |
| title_sort |
genetics of parathyroid tumours |
| topic |
Internal Medicine |
| url |
http://dx.doi.org/10.1111/joim.12523 |
| publishDate |
2016 |
| physical |
574-583 |
| description |
<jats:title>Abstract</jats:title><jats:p>Primary hyperparathyroidism (<jats:styled-content style="fixed-case">PHPT</jats:styled-content>), due to parathyroid tumours, may occur as part of a complex syndrome or as an isolated (nonsyndromic) disorder, and both forms can occur as familial (i.e. hereditary) or nonfamilial (i.e. sporadic) disease. Syndromic <jats:styled-content style="fixed-case">PHPT</jats:styled-content> includes multiple endocrine neoplasia (<jats:styled-content style="fixed-case">MEN</jats:styled-content>) types 1 to 4 (<jats:styled-content style="fixed-case">MEN</jats:styled-content>1 to <jats:styled-content style="fixed-case">MEN</jats:styled-content>4) and the hyperparathyroidism‐jaw tumour (<jats:styled-content style="fixed-case">HPT</jats:styled-content>‐<jats:styled-content style="fixed-case">JT</jats:styled-content>) syndrome. Syndromic and hereditary <jats:styled-content style="fixed-case">PHPT</jats:styled-content> are often associated with multiple parathyroid tumours, in contrast to sporadic <jats:styled-content style="fixed-case">PHPT</jats:styled-content>, in which single parathyroid adenomas are more common. In addition, parathyroid carcinomas may occur in ~15% of patients with the <jats:styled-content style="fixed-case">HPT</jats:styled-content>‐<jats:styled-content style="fixed-case">JT</jats:styled-content> syndrome. <jats:styled-content style="fixed-case">MEN</jats:styled-content>1 is caused by abnormalities of the <jats:italic><jats:styled-content style="fixed-case">MEN</jats:styled-content>1</jats:italic> gene which encodes a tumour suppressor; <jats:styled-content style="fixed-case">MEN</jats:styled-content>2 and <jats:styled-content style="fixed-case">MEN</jats:styled-content>3 are due to mutations of the rearranged during transfection (<jats:italic><jats:styled-content style="fixed-case">RET</jats:styled-content></jats:italic>) proto‐oncogene, which encodes a tyrosine kinase receptor; <jats:styled-content style="fixed-case">MEN</jats:styled-content>4 is due to mutations of a cyclin‐dependent kinase inhibitor (<jats:italic><jats:styled-content style="fixed-case">CDNK</jats:styled-content>1B</jats:italic>); and <jats:styled-content style="fixed-case">HPT</jats:styled-content>‐<jats:styled-content style="fixed-case">JT</jats:styled-content> is due to mutations of cell division cycle 73 (<jats:italic><jats:styled-content style="fixed-case">CDC</jats:styled-content>73</jats:italic>), which encodes parafibromin. Nonsyndromic <jats:styled-content style="fixed-case">PHPT</jats:styled-content>, which may be hereditary and referred to as familial isolated hyperparathyroidism, may also be due to <jats:italic><jats:styled-content style="fixed-case">MEN</jats:styled-content>1, <jats:styled-content style="fixed-case">CDC</jats:styled-content>73</jats:italic> or calcium‐sensing receptor (<jats:italic><jats:styled-content style="fixed-case">CASR</jats:styled-content></jats:italic>) mutations. In addition, ~10% of patients presenting below the age of 45 years with nonsyndromic, sporadic <jats:styled-content style="fixed-case">PHPT</jats:styled-content> may have <jats:italic><jats:styled-content style="fixed-case">MEN</jats:styled-content>1</jats:italic>,<jats:italic> <jats:styled-content style="fixed-case">CDC</jats:styled-content>73</jats:italic> or <jats:italic><jats:styled-content style="fixed-case">CASR</jats:styled-content></jats:italic> mutations, and overall more than 10% of patients with <jats:styled-content style="fixed-case">PHPT</jats:styled-content> will have a mutation in one of 11 genes. Genetic testing is available and of value in the clinical setting, as it helps in making the correct diagnosis and planning the management of these complex disorders associated with parathyroid tumours.</jats:p> |
| container_issue |
6 |
| container_start_page |
574 |
| container_title |
Journal of Internal Medicine |
| container_volume |
280 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792347430772015106 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T17:55:09.993Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Genetics+of+parathyroid+tumours&rft.date=2016-12-01&genre=article&issn=1365-2796&volume=280&issue=6&spage=574&epage=583&pages=574-583&jtitle=Journal+of+Internal+Medicine&atitle=Genetics+of+parathyroid+tumours&aulast=Thakker&aufirst=R.+V.&rft_id=info%3Adoi%2F10.1111%2Fjoim.12523&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792347430772015106 |
| author | Thakker, R. V. |
| author_facet | Thakker, R. V., Thakker, R. V. |
| author_sort | thakker, r. v. |
| container_issue | 6 |
| container_start_page | 574 |
| container_title | Journal of Internal Medicine |
| container_volume | 280 |
| description | <jats:title>Abstract</jats:title><jats:p>Primary hyperparathyroidism (<jats:styled-content style="fixed-case">PHPT</jats:styled-content>), due to parathyroid tumours, may occur as part of a complex syndrome or as an isolated (nonsyndromic) disorder, and both forms can occur as familial (i.e. hereditary) or nonfamilial (i.e. sporadic) disease. Syndromic <jats:styled-content style="fixed-case">PHPT</jats:styled-content> includes multiple endocrine neoplasia (<jats:styled-content style="fixed-case">MEN</jats:styled-content>) types 1 to 4 (<jats:styled-content style="fixed-case">MEN</jats:styled-content>1 to <jats:styled-content style="fixed-case">MEN</jats:styled-content>4) and the hyperparathyroidism‐jaw tumour (<jats:styled-content style="fixed-case">HPT</jats:styled-content>‐<jats:styled-content style="fixed-case">JT</jats:styled-content>) syndrome. Syndromic and hereditary <jats:styled-content style="fixed-case">PHPT</jats:styled-content> are often associated with multiple parathyroid tumours, in contrast to sporadic <jats:styled-content style="fixed-case">PHPT</jats:styled-content>, in which single parathyroid adenomas are more common. In addition, parathyroid carcinomas may occur in ~15% of patients with the <jats:styled-content style="fixed-case">HPT</jats:styled-content>‐<jats:styled-content style="fixed-case">JT</jats:styled-content> syndrome. <jats:styled-content style="fixed-case">MEN</jats:styled-content>1 is caused by abnormalities of the <jats:italic><jats:styled-content style="fixed-case">MEN</jats:styled-content>1</jats:italic> gene which encodes a tumour suppressor; <jats:styled-content style="fixed-case">MEN</jats:styled-content>2 and <jats:styled-content style="fixed-case">MEN</jats:styled-content>3 are due to mutations of the rearranged during transfection (<jats:italic><jats:styled-content style="fixed-case">RET</jats:styled-content></jats:italic>) proto‐oncogene, which encodes a tyrosine kinase receptor; <jats:styled-content style="fixed-case">MEN</jats:styled-content>4 is due to mutations of a cyclin‐dependent kinase inhibitor (<jats:italic><jats:styled-content style="fixed-case">CDNK</jats:styled-content>1B</jats:italic>); and <jats:styled-content style="fixed-case">HPT</jats:styled-content>‐<jats:styled-content style="fixed-case">JT</jats:styled-content> is due to mutations of cell division cycle 73 (<jats:italic><jats:styled-content style="fixed-case">CDC</jats:styled-content>73</jats:italic>), which encodes parafibromin. Nonsyndromic <jats:styled-content style="fixed-case">PHPT</jats:styled-content>, which may be hereditary and referred to as familial isolated hyperparathyroidism, may also be due to <jats:italic><jats:styled-content style="fixed-case">MEN</jats:styled-content>1, <jats:styled-content style="fixed-case">CDC</jats:styled-content>73</jats:italic> or calcium‐sensing receptor (<jats:italic><jats:styled-content style="fixed-case">CASR</jats:styled-content></jats:italic>) mutations. In addition, ~10% of patients presenting below the age of 45 years with nonsyndromic, sporadic <jats:styled-content style="fixed-case">PHPT</jats:styled-content> may have <jats:italic><jats:styled-content style="fixed-case">MEN</jats:styled-content>1</jats:italic>,<jats:italic> <jats:styled-content style="fixed-case">CDC</jats:styled-content>73</jats:italic> or <jats:italic><jats:styled-content style="fixed-case">CASR</jats:styled-content></jats:italic> mutations, and overall more than 10% of patients with <jats:styled-content style="fixed-case">PHPT</jats:styled-content> will have a mutation in one of 11 genes. Genetic testing is available and of value in the clinical setting, as it helps in making the correct diagnosis and planning the management of these complex disorders associated with parathyroid tumours.</jats:p> |
| doi_str_mv | 10.1111/joim.12523 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTExMS9qb2ltLjEyNTIz |
| imprint | Wiley, 2016 |
| imprint_str_mv | Wiley, 2016 |
| institution | DE-D161, DE-Zwi2, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1 |
| issn | 1365-2796, 0954-6820 |
| issn_str_mv | 1365-2796, 0954-6820 |
| language | English |
| last_indexed | 2024-03-01T17:55:09.993Z |
| match_str | thakker2016geneticsofparathyroidtumours |
| mega_collection | Wiley (CrossRef) |
| physical | 574-583 |
| publishDate | 2016 |
| publishDateSort | 2016 |
| publisher | Wiley |
| record_format | ai |
| recordtype | ai |
| series | Journal of Internal Medicine |
| source_id | 49 |
| spelling | Thakker, R. V. 0954-6820 1365-2796 Wiley Internal Medicine http://dx.doi.org/10.1111/joim.12523 <jats:title>Abstract</jats:title><jats:p>Primary hyperparathyroidism (<jats:styled-content style="fixed-case">PHPT</jats:styled-content>), due to parathyroid tumours, may occur as part of a complex syndrome or as an isolated (nonsyndromic) disorder, and both forms can occur as familial (i.e. hereditary) or nonfamilial (i.e. sporadic) disease. Syndromic <jats:styled-content style="fixed-case">PHPT</jats:styled-content> includes multiple endocrine neoplasia (<jats:styled-content style="fixed-case">MEN</jats:styled-content>) types 1 to 4 (<jats:styled-content style="fixed-case">MEN</jats:styled-content>1 to <jats:styled-content style="fixed-case">MEN</jats:styled-content>4) and the hyperparathyroidism‐jaw tumour (<jats:styled-content style="fixed-case">HPT</jats:styled-content>‐<jats:styled-content style="fixed-case">JT</jats:styled-content>) syndrome. Syndromic and hereditary <jats:styled-content style="fixed-case">PHPT</jats:styled-content> are often associated with multiple parathyroid tumours, in contrast to sporadic <jats:styled-content style="fixed-case">PHPT</jats:styled-content>, in which single parathyroid adenomas are more common. In addition, parathyroid carcinomas may occur in ~15% of patients with the <jats:styled-content style="fixed-case">HPT</jats:styled-content>‐<jats:styled-content style="fixed-case">JT</jats:styled-content> syndrome. <jats:styled-content style="fixed-case">MEN</jats:styled-content>1 is caused by abnormalities of the <jats:italic><jats:styled-content style="fixed-case">MEN</jats:styled-content>1</jats:italic> gene which encodes a tumour suppressor; <jats:styled-content style="fixed-case">MEN</jats:styled-content>2 and <jats:styled-content style="fixed-case">MEN</jats:styled-content>3 are due to mutations of the rearranged during transfection (<jats:italic><jats:styled-content style="fixed-case">RET</jats:styled-content></jats:italic>) proto‐oncogene, which encodes a tyrosine kinase receptor; <jats:styled-content style="fixed-case">MEN</jats:styled-content>4 is due to mutations of a cyclin‐dependent kinase inhibitor (<jats:italic><jats:styled-content style="fixed-case">CDNK</jats:styled-content>1B</jats:italic>); and <jats:styled-content style="fixed-case">HPT</jats:styled-content>‐<jats:styled-content style="fixed-case">JT</jats:styled-content> is due to mutations of cell division cycle 73 (<jats:italic><jats:styled-content style="fixed-case">CDC</jats:styled-content>73</jats:italic>), which encodes parafibromin. Nonsyndromic <jats:styled-content style="fixed-case">PHPT</jats:styled-content>, which may be hereditary and referred to as familial isolated hyperparathyroidism, may also be due to <jats:italic><jats:styled-content style="fixed-case">MEN</jats:styled-content>1, <jats:styled-content style="fixed-case">CDC</jats:styled-content>73</jats:italic> or calcium‐sensing receptor (<jats:italic><jats:styled-content style="fixed-case">CASR</jats:styled-content></jats:italic>) mutations. In addition, ~10% of patients presenting below the age of 45 years with nonsyndromic, sporadic <jats:styled-content style="fixed-case">PHPT</jats:styled-content> may have <jats:italic><jats:styled-content style="fixed-case">MEN</jats:styled-content>1</jats:italic>,<jats:italic> <jats:styled-content style="fixed-case">CDC</jats:styled-content>73</jats:italic> or <jats:italic><jats:styled-content style="fixed-case">CASR</jats:styled-content></jats:italic> mutations, and overall more than 10% of patients with <jats:styled-content style="fixed-case">PHPT</jats:styled-content> will have a mutation in one of 11 genes. Genetic testing is available and of value in the clinical setting, as it helps in making the correct diagnosis and planning the management of these complex disorders associated with parathyroid tumours.</jats:p> Genetics of parathyroid tumours Journal of Internal Medicine |
| spellingShingle | Thakker, R. V., Journal of Internal Medicine, Genetics of parathyroid tumours, Internal Medicine |
| title | Genetics of parathyroid tumours |
| title_full | Genetics of parathyroid tumours |
| title_fullStr | Genetics of parathyroid tumours |
| title_full_unstemmed | Genetics of parathyroid tumours |
| title_short | Genetics of parathyroid tumours |
| title_sort | genetics of parathyroid tumours |
| title_unstemmed | Genetics of parathyroid tumours |
| topic | Internal Medicine |
| url | http://dx.doi.org/10.1111/joim.12523 |